Fees, non-financial support and other from Chiesi, Astrazeneca, GlaxoSmithKline, Boehringer Ingelheim, Merck Sharp Dohme, Pfizer, Takeda, and Mundipharma (outdoors the submitted perform); individual charges and non-financial assistance from Menarini, Novartis, and Zambon. Professor Jones reports personal fees fromsubmit your manuscript | www.dovepress.comInternational Journal of COPD 2015:DovepressDovepressFluticasone propionate/formoterol in COPD 16. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in a single hydrofluoroalkane pressurized metereddose inhaler in patients with chronic obstructive pulmonary disease: benefits from a 1-year randomized controlled clinical trial. Drugs. 2009; 69(five):54965. 17. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):21023. 18. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and influence on patient outcomes.4-Fluoro-7-azaindole Purity COPD. 2009;6(five):32029. 19. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008; 102(eight):1099108. 20. Rossi A, Kristufek P, Levine BE, et al; Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison in the efficacy, tolerability, and safety of formoterol dry powder and oral, slowrelease theophylline within the remedy of COPD. Chest. 2002;121(4): 1058069. 21. Dahl R, Greefhorst LA, Nowak D, et al; Formoterol in Chronic Obstructive Pulmonary Illness I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary illness. Am J Respir Crit Care Med. 2001;164(five):77884. 22. Bateman ED, Bleecker ER, L vall J, et al. Dose impact of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012;106(five):64250. 23. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med. 1999;93(three):16166. 24. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al; Groningen Leiden Universities Corticosteroids in Obstructive Lung Illness Study Group. Impact of fluticasone with and with out salmeterol on pulmonary outcomes in chronic obstructive pulmonary illness: a randomized trial. Ann Intern Med. 2009;151(8):51727. 25. Magnussen H, Disse B, Rodriguez-Roisin R, et al; WISDOM Investigators.Formula of 362522-50-7 Withdrawal of inhaled glucocorticoids and exacerbations of COPD.PMID:24275718 N Engl J Med. 2014;371:1285294. 26. European Medicines Agency. Guideline on Clinical Development of Fixed Dose Mixture Medicinal Goods. EMA/ CHMP/281825/2015. London: European Medicines Agency; 2015. Accessible from: http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2015/05/WC500186840.pdf. Accessed July 16, 2015. 27. ICH Harmonised Tripartite Guideline: Selection of Manage Group and Related Concerns in Clinical Trials. E10. ICH; 2000. Readily available from: http:// www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/ Efficacy/E10/Step4/E10_Guideline.pdf. Accessed July 16, 2015. 28. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The preventi.